chromium

Small moleculeexperimental

Nearly 60 years ago, chromium, as the trivalent ion, was proposed to be an essential element, but the results of new studies indicate that chromium currently can only be considered pharmacologically active and not an essential element. Chromium is a mineral that humans need in very small quantities. Good sources include broccoli, liver, and brewers' yeast. Taking chromium by mouth is effective for preventing chromium deficiency. It is also taken by mouth for depression, Turner's syndrome, polycystic ovary syndrome (PCOS), lowering "bad" cholesterol, raising "good" cholesterol in people taking heart medications called beta blockers, obesity, metabolic syndrome, heart attack, schizophrenia, bipolar disorder, binge eating disorder, and a disease called reactive hypoglycemia. Chromium has been marketed as an agent to reduce body mass and develop muscle; however, such marketing claims are no longer allowed in the United States because they are not supported by experiments. Trivalent chromium has also been proposed as a therapeutic agent to increase insulin sensitivity and affect lipid metabolism. Although effective in certain rodent models, beneficial effects in humans have not been unequivocally established. — NCATS

Clinical trial activity

11 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
1

Earliest trial started Apr 1, 2005 (NCT00067626)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

[Cr]
Mol. weight
51.9961 g/mol
Chirality
Achiral Molecule
Inorganic
Yes
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • chromium
  • chromium
  • chromium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06405243Phase 3Jun 30, 2024Beni Suef University
NCT06709313Phase 4Jun 3, 2024Fayoum University
NCT05545020Phase 2/Phase 3 (Phase 3)Dec 31, 2022Alexandria University
NCT04511468N/AJun 23, 2021Blackmores Institute, University of Indonesia
NCT05573607N/ANov 19, 2020Keller Consulting Group, Mend Nutrition, Inc, The Center for Applied Health Sciences, LLC
NCT06641596N/AFeb 1, 2019Kerry
NCT03552315N/AApr 24, 2018DoubleGood AB, Lund University
NCT03503201N/AApr 23, 2018Cairo University
NCT01107431N/ADec 1, 2008Georgetown University, Integrative Health Technologies
NCT00846248N/AJan 1, 2006University of California, San Francisco
NCT00067626Phase 2Apr 1, 2005National Center for Complementary and Integrative Health (NCCIH), Yale University
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alexandria UniversityAcademic/Hospital1112022
Beni Suef UniversityAcademic/Hospital1112024
Blackmores InstituteAcademic/Hospital1012021
Cairo UniversityAcademic/Hospital1112018
DoubleGood ABFor profit1112018
Fayoum UniversityAcademic/Hospital1112024
Georgetown UniversityAcademic/Hospital1012008
Integrative Health TechnologiesFor profit1112008
Keller Consulting GroupFor profit1012020
KerryFor profit1112019
Lund UniversityAcademic/Hospital1012018
Mend Nutrition, IncFor profit1012020
National Center for Complementary and Integrative Health (NCCIH)Government1012005
The Center for Applied Health Sciences, LLCAcademic/Hospital1112020
University of California, San FranciscoAcademic/Hospital1112006
University of IndonesiaAcademic/Hospital1112021
Yale UniversityAcademic/Hospital1112005
17 organizations
Page 1 / 1